Animal model

An interdisciplinary research team involving the German Center for Infection Research (DZIF) has identified two antiviral drug candidates effective against a wide range of viruses. The study

The Health Emergency Preparedness and Response Authority (HERA) of the European Commission, through the European Health and Digital Executive Agency (HaDEA) supports the establishment of the “European

An international research group led by scientists of the German Center for Infection Research (DZIF) at the Helmholtz Centre for Infection Research (HZI) has discovered a promising new drug candidate

Every year, 10 million people contract tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), and approximately 1.5 million patients succumb to the disease. Treatment

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)

Two DZIF junior scientists—Prof Philipp Schommers and Dr Alexander Simonis—have been honoured with silver medals by the Walter Siegenthaler Society for their fundamental medical research in the field

Antibacterial drugs are important for treating infections. However, increasing bacterial resistance to current drugs—making them ineffective or only partially effective—means that new drugs are

The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine